TRAF4 may be a viable therapeutic target
Previous research has shown that uncontrolled tissue repair is associated with tumor formation (tumorigenesis), although the direct connection between the two was not previously been well defined.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Lerner Research Institute scientists, led by Xiaoxia Li, PhD, Department of Inflammation & Immunity, discovered a new signaling pathway in a subset of hair follicle stem cells that mechanistically links for the first time inflammation, wound healing and tumorigenesis, offering new insights into this disease-driving process and suggesting a potential target to slow or prevent tumor initiation.
The research team found in a preclinical model that the proinflammatory cytokine IL-17A (interleukin-17A)—of which high levels are associated with several chronic inflammatory diseases and cancer—plays a critical role in aberrant tissue repair. When IL-17A signaling was “turned on,” Lrig1+ stem cells, found in the skin’s hair follicles, multiplied and their progeny translocated to other layers of the skin in response to injury and there played an active role in epidermal tumorigenesis.
Looking to take their investigation a step further, the researchers set out to understand what happens between activation of the IL-17A signaling cascade and tumorigenesis, as they knew the “in between” is where an actionable therapeutic target is likely to live.
Through a series of signaling assays, Dr. Li and collaborators showed that the presence and physical proximity of a series of proteins sets into motion a complex signaling cascade that results in activation of ERK5 (extracellular signal regulated kinase 5), which is ultimately responsible for the expansion and migration of Lrig1+ stem cells. While many proteins—including IL-17R (interleukin-17 receptor), EGFR (epidermal growth factor receptor) and Act1—are involved, TRAF4 (tumor necrosis factor receptor associated factor 4) is the first domino to fall, setting the entire signaling cascade in motion.
“This study is important for two reasons. On one hand, it is the first study to show that a proinflammatory cytokine can recruit a growth factor receptor to activate stem cells in support of tissue repair and tumorigenesis,” explains Dr. Li. “It also identified TRAF4’s upstream role in tumor development.”
Considered together with the fact that others in the field have found the protein to also aid in tumor growth, the team believes TRAF4 may be a viable therapeutic target to pursue in future studies.
Xing Chen, PhD, is first author on the study, which was published in the Journal of Experimental Medicine, and supported by grants from the National Cancer Institute and National Heart, Lung, and Blood Institute, both parts of the National Institutes of Health. Dr. Li holds the Paul L. Fox, PhD, Endowed Chair in Molecular Medicine at Cleveland Clinic’s Lerner Research Institute. Drs. Brian Gastman, Jennifer Ko, Shlomo Koyfman and Allison Vidimos provided insight into the clinical relevance of this study.
Investigators are developing a deep learning model to predict health outcomes in ICUs.
Cleveland Clinic and Johns Hopkins collaboration could help meet need for new therapies
Cleveland Clinic researchers’ finding paves the way for new antiviral approaches
Multicenter collaboration aims to facilitate tracking of neurological activity deep within tissue
Findings illuminate MCEMP1 protein’s role in severe inflammation
Anti-viral immunity identified a novel mechanism in necroptosis
Cleveland Clinic’s new Global Director of Vaccine Development outlines plans, priorities
Collaborative involving Cleveland Clinic investigators focuses on antiviral drug development